These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11774975)

  • 21. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole.
    Fontaine C; Bousquet PJ; Demoly P
    J Allergy Clin Immunol; 2005 Mar; 115(3):633-4. PubMed ID: 15753917
    [No Abstract]   [Full Text] [Related]  

  • 23. A comparison of the renal and cardiovascular safety of celecoxib and rofecoxib.
    Schoors D
    Clin Ther; 2002 Mar; 24(3):468-9; author reply 469-70. PubMed ID: 11952030
    [No Abstract]   [Full Text] [Related]  

  • 24. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database.
    Lugardon S; Lapeyre-Mestre M; Montastruc JL
    Eur J Clin Pharmacol; 2004 Nov; 60(9):673-7. PubMed ID: 15517227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk associated with celecoxib.
    Brophy JM
    N Engl J Med; 2005 Jun; 352(25):2648-50; author reply 2648-50. PubMed ID: 15972876
    [No Abstract]   [Full Text] [Related]  

  • 26. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS; Nourjah P; Grosser SC; Graham DJ
    Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous vasculitis induced by cyclo-oxygenase-2 selective inhibitors.
    Drago F; Brusati C; Desirello G; Cacciapuoti M; Rebora A
    J Am Acad Dermatol; 2004 Dec; 51(6):1029-30. PubMed ID: 15583611
    [No Abstract]   [Full Text] [Related]  

  • 29. [Selective cyclooxygenase-2 inhibitors and the digestive tract].
    Chaabouni H; Amouri A; Cheikh I; Kchaou M; Ouerghi H; Ben Mami N; Ben Ammar A
    Tunis Med; 2002 Aug; 80(8):427-33. PubMed ID: 12703120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
    Wolfe F; Flowers N; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 May; 29(5):1015-22. PubMed ID: 12022317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A critical evaluation of side effect data on COX-2 inhibitors].
    Pomp E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):476-80. PubMed ID: 11961974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
    Lee YH; Ji JD; Song GG
    Rheumatol Int; 2007 Mar; 27(5):477-82. PubMed ID: 17051359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
    [No Abstract]   [Full Text] [Related]  

  • 34. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is concern about cardiovascular events with the new coxib class of drugs justified?
    Schnitzer TJ
    Medscape Womens Health; 2001 Oct; 6(5):8. PubMed ID: 11698930
    [No Abstract]   [Full Text] [Related]  

  • 37. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
    Weaver A; Alderman M; Sperling R
    Am J Cardiol; 2003 May; 91(10):1291-2. PubMed ID: 12745131
    [No Abstract]   [Full Text] [Related]  

  • 39. Differences between COX-2-specific inhibitors: clinical and economic implications.
    Sonnenblick EH
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792
    [No Abstract]   [Full Text] [Related]  

  • 40. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
    Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.